Understanding how alpha-synuclein affects brain circuits in Parkinson's disease and dementia
Reciprocal interactions between cortical circuit dysfunction and α-synuclein pathology
This study is looking at how a protein called alpha-synuclein affects brain function in people with Parkinson's disease and Dementia with Lewy Bodies, hoping to find new ways to help improve thinking and memory for those living with these conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11010357 on NIH RePORTER |
What this research studies
This research investigates the relationship between alpha-synuclein protein accumulation and the dysfunction of brain circuits in Parkinson's disease and Dementia with Lewy Bodies. The team will explore how the presence of this protein disrupts neuronal activity and how changes in brain activity may influence the accumulation of alpha-synuclein. By utilizing advanced imaging techniques, they aim to uncover the mechanisms behind cognitive impairment associated with these neurodegenerative diseases. The findings could lead to new insights into potential therapeutic targets for improving cognitive function in affected patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Parkinson's disease or Dementia with Lewy Bodies who are experiencing cognitive impairment.
Not a fit: Patients with other forms of dementia not related to alpha-synuclein pathology may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of therapies that modify the progression of cognitive impairment in Parkinson's disease and related dementias.
How similar studies have performed: Previous research has shown promising results in understanding the role of alpha-synuclein in neurodegenerative diseases, but this specific approach is novel and aims to fill critical knowledge gaps.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Zeiger, William Abel — University of California Los Angeles
- Study coordinator: Zeiger, William Abel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.